Latest Interviews
Showing 16–17 of 17 transcripts.
Clear all filters- All-In Podcast1h 25m
E97: SPAC updates, public/private market overview, Putin's end game & more
Putin, Chamath, Calacanis, Friedberg, Jake, Nick, David, Jason, Sacks
Chamath Palihapitiya announced the liquidation of his IPOD and IPOF SPACs to return capital to investors, citing an unsustainable market environment where valuation gaps and volatility have frozen exits for late-stage private companies. He forecast a catastrophic "washout" for the broader SPAC sector while criticizing systemic failures in venture capital diligence and ESG frameworks that obscure financial reality. The discussion further addressed looming geopolitical risks, including escalation in Ukraine and protests in Iran, arguing that institutional decay and demographic shifts are driving instability that requires a nuanced diplomatic approach rather than intervention.
- Milken Institute58 min
The Role of Universities in Accelerating Bioscience Research
David Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
A consortium of leading academic figures, including Nobel Laureate David Baltimore and experts from Caltech, UCLA, and USC, convened to evaluate the intersection of biological engineering and clinical translation in the face of funding constraints. The panel detailed successful strategies for "engineered immunity" projects, such as converting muscle cells into antibody producers and conducting early-stage human trials within university settings, while highlighting the critical need for interdisciplinary programs that bridge the gap between engineering PhDs and MDs. Despite progress, participants identified a persistent "valley of death" in early-stage financing and urged a cultural shift toward professional management and team-based funding mechanisms to sustain innovation.